ما هو علاج ابيضاض الدم / الليمفوما من الخلايا التائية للبالغين النوع الكامد العرضي أو المزمن؟

References

• Zidovudine-interferon-a (IFN-a) can be recommended for patients with symptomatic smouldering (skin or lung lesions, opportunistic infections), primary cutaneous with tumoural lesions or chronic ATLL [III, B; not EMA or FDA approved], along with skin-directed therapy in case of skin lesions [III, B].
• Monotherapy with mogamulizumab (if CCR4-positive; not EMA or FDA approved), BV (if CD30-positive; not EMA or FDA approved), alemtuzumab (if CD52-positive; not EMA or FDA approved) or lenalidomide (not EMA or FDA approved) can be considered [III, B].
• Allo-HSCT (if not used in first line) should be considered in HSCT-eligible responding patients [III, A].